Patents Assigned to Barrier Therapeutics, Inc.
  • Enhanced delivery of antioxidants for treatment of central nervous system disorders involving oxidative stress
    Patent number: 11612642
    Abstract: The present disclosure generally relates to methods and formulations for treating central nervous system (CNS) disorders. The present disclosure involves intranasal delivery of at least one antioxidant compound, allowing for effective treatment of a central nervous system disorder such as traumatic brain injury or stroke.
    Type: Grant
    Filed: April 27, 2020
    Date of Patent: March 28, 2023
    Assignee: Beyond Barriers Therapeutics, Inc.
    Inventors: Ryan Kole, John Marshall, Meriel Owen
  • Itraconazole compositions with improved bioavailability
    Patent number: 9149431
    Abstract: A solid dispersion product comprising itraconazole and hydroxypropyl methylcellulose, which satisfies the Formula 0.35>?Htr (1) (wherein ?Htr represents the endotherm (J/g) accompanying a transition at about 240° C.). The solid dispersion product shows an improved bioavailability.
    Type: Grant
    Filed: June 21, 2013
    Date of Patent: October 6, 2015
    Assignees: Abbvie Deutschland GmbH & Co KG, Barrier Therapeutics, Inc.
    Inventors: Gunther Berndl, Matthias Degenhardt, Markus Mägerlein, Gerrit Dispersyn
  • Modified azole compounds as antifungal and antibacterial agents
    Patent number: 8147852
    Abstract: The present invention relates to the compounds of formula (I), their preparation and use as antifungal and/or antibacterial agents. where the values for R1, R2, R3, R4, R5 and A are as defined herein.
    Type: Grant
    Filed: April 23, 2008
    Date of Patent: April 3, 2012
    Assignee: Barrier Therapeutics, Inc.
    Inventors: Marcel Borgers, Maarten van Geffen, Jannie Ausma